Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : PFE save search
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Published: 2022-06-17 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 3.13%
H: 8.66%
C: 6.63%
sciences women lancet therapy publication phase 3
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-30 (Crawled : 01:00) - prnewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.87%
H: 0.98%
C: -1.43%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results phase 3 topline ulcerative colitis
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Published: 2022-03-23 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
trial positive results phase 3 topline ulcerative colitis
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
Published: 2022-03-01 (Crawled : 13:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
trial disease potential vaccine phase 3
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published: 2022-01-12 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.77%
H: 1.46%
C: 0.55%
phase 3 topline order
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | News | $88.24 0.26% 180K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Published: 2021-10-21 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.6%
H: 0.08%
C: -0.45%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
BNTX | News | $88.24 0.26% 180K
|
Health Technology
|
| O: 2.66%
H: 3.69%
C: 3.53%
covid vaccine phase 3 trial
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
Published: 2021-09-17 (Crawled : 22:00) - prnewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
| Email alert
Add to watchlist
risk prostate cancer cancer phase 3 hormone
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Published: 2021-09-02 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.96%
H: 0.84%
C: 0.77%
respiratory vaccine phase 3 trial
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Published: 2021-08-30 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -2.47%
H: 2.08%
C: 1.21%
positive results dermatitis phase 3 trial topline atopic dermatitis
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.05%
H: 0.08%
C: -1.46%
prostate cancer cancer phase 3
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
Published: 2021-04-12 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.33%
H: 1.52%
C: 1.34%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.39%
H: 0.5%
C: -4.98%
phase 3 contraceptive
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-03-24 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.34%
H: 1.27%
C: 0.37%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 0.3%
H: 1.17%
C: -7.12%
positive therapy women phase 3
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Published: 2021-03-23 (Crawled : 18:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.5%
H: 0.31%
C: -1.28%
phase 1 antiviral phase 3 phase 2 sars-cov-2
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Published: 2021-02-17 (Crawled : 22:04) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.32%
H: 0.28%
C: -0.63%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -0.89%
H: 3.7%
C: 3.11%
therapy women phase 3
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Published: 2021-01-26 (Crawled : 12:00) - globenewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: -0.03%
H: 0.89%
C: 0.11%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: 4.44%
H: 9.52%
C: 4.67%
positive therapy phase 3
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
Published: 2021-01-07 (Crawled : 19:00) - biospace.com/
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.46%
H: 0.3%
C: 0.05%
gene therapy therapy phase 3 duchenne gene therapies
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.